HIMS240705C21000
- 0.01
- -0.14-93.33%
Hims & Hers Health Newsroom
Form 144 | Hims & Hers Health(HIMS.US) Officer Proposes to Sell 361.14K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 5, $Hims & Hers Health(HIMS.US)$ Officer Melissa Baird intends to sell 17,625 shares of its common stock on Jul 5, with a total market value of approximately $361.14K. Me
'Ozempic May Lower Risk of Obesity-Related Cancers, Study Finds' - Bloomberg Law
'Ozempic May Lower Risk of Obesity-Related Cancers, Study Finds' - Bloomberg Law
Peering Into Hims & Hers Health's Recent Short Interest
Hims & Hers Health's (NYSE:HIMS) short percent of float has fallen 19.64% since its last report. The company recently reported that it has 17.00 million shares sold short, which is 9.04% of all regula
Biden Urges Novo Nordisk To Cut Ozempic And Wegovy Prices
Biden Urges Novo Nordisk To Cut Ozempic And Wegovy Prices
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.
Social Buzz: Wallstreetbets Stocks Mostly Higher Pre-Bell Friday; Trump Media & Technology Group to Advance, Nike to Decline
The most-talked-about stocks in the Reddit subforum Wallstreetbets were mostly higher hours before Friday's opening bell. Trump Media & Technology Group (DJT) was 9% higher premarket, reversing a 6.4%
Hims & Hers Shares Fall on Hunterbrook Report That GLP-1 Drugs Come From 'Shady Supplier'
Correction to Hims & Hers Down Article
Hims & Hers Health executives, including the chief executive officer and chief legal officer, have sold more than 1.7 million shares, realizing $26.4 million of net proceeds since May 20. "Hims & Hers
Hims & Hers Health Options Spot-On: On June 27th, 118.11K Contracts Were Traded, With 330.13K Open Interest
On June 27th ET, $Hims & Hers Health(HIMS.US)$ had active options trading, with a total trading volume of 118.11K options for the day, of which put options accounted for 44.86% of the total transactio
Hims & Hers Health Stock Is Sliding Thursday: What's Going On?
Hims & Hers Health, Inc (NYSE:HIMS) shares are trading lower Thursday after Hunterbrook issued a short report on the stock.What Happened: Hunterbrook released a bearish report on Thursday, alleging Hi
Hims & Hers Down Sharply Again as Scrutiny Over Ozempic Knockoff Business Grows -- WSJ
By David Wainer Shares of Hims & Hers, the telehealth company, are under pressure as scrutiny of its weight loss business intensifies. On Wednesday, Heard on the Street argued that Himss 150% stock
Jefferies Maintains Hold on Hims & Hers Health, Raises Price Target to $23
Jefferies analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $14 to $23.
Hims & Hers Health Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 18.68% Jefferies $14 → $23 Maintains Hold 06/13/2024 34.16% B of A Securities $22 → $26 Maintai
Him & Hers Down 6% Following Report on 'Shady Supplier' for Weight Loss Drug
Express News | Hims & Hers Health Shares Drop 11.6% Premarket After Hunterbrook Capital Short on Co
Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Thursday.Shares of Levi Strauss & Co. (NYSE:LEVI) fell sharply in today's pre-market trading after the compan
Jefferies Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Raises Target Price to $23
Jefferies analyst Glen Santangelo maintains $Hims & Hers Health(HIMS.US)$ with a hold rating, and adjusts the target price from $15 to $23.According to TipRanks data, the analyst has a success rate of
Watching Hims & Hers Health Shares, Hunterbrook Issues Short Report
Watching Hims & Hers Health Shares, Hunterbrook Issues Short Report
Express News | Hims & Hers Health Inc : Jefferies Raises Target Price to $23 From $14
Is it not good news for investors that multi-component drugs are joining the battle of GLP weight loss drugs?
Due to possible regulatory pressure and lawsuits, the growth in supply of weight loss drugs may squeeze the living space of compound drugs, and this seemingly prosperous market may bring potential risks to investors of compound drugs.